Tonix Pharmaceuticals (NASDAQ:TNXP) Issues Quarterly Earnings Results

Tonix Pharmaceuticals (NASDAQ:TNXPGet Free Report) issued its quarterly earnings data on Monday. The company reported ($0.86) EPS for the quarter, reports. The company had revenue of $3.78 million for the quarter, compared to analyst estimates of $3.95 million.

Tonix Pharmaceuticals Stock Performance

TNXP opened at $0.19 on Wednesday. Tonix Pharmaceuticals has a twelve month low of $0.17 and a twelve month high of $3.80. The company has a fifty day moving average of $0.33 and a 200-day moving average of $0.44.

Institutional Investors Weigh In On Tonix Pharmaceuticals

Large investors have recently modified their holdings of the company. Two Sigma Investments LP increased its position in shares of Tonix Pharmaceuticals by 183.9% during the first quarter. Two Sigma Investments LP now owns 60,191 shares of the company’s stock worth $36,000 after buying an additional 38,991 shares during the period. UBS Group AG increased its position in shares of Tonix Pharmaceuticals by 18,868.5% during the fourth quarter. UBS Group AG now owns 67,528 shares of the company’s stock worth $26,000 after buying an additional 67,172 shares during the period. Millennium Management LLC grew its holdings in Tonix Pharmaceuticals by 448.2% in the second quarter. Millennium Management LLC now owns 140,414 shares of the company’s stock worth $222,000 after purchasing an additional 114,801 shares during the period. Raymond James & Associates acquired a new stake in Tonix Pharmaceuticals in the fourth quarter worth $65,000. Finally, Virtu Financial LLC grew its holdings in Tonix Pharmaceuticals by 44.8% in the fourth quarter. Virtu Financial LLC now owns 188,075 shares of the company’s stock worth $73,000 after purchasing an additional 58,184 shares during the period. 82.26% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities analysts recently commented on TNXP shares. Dawson James began coverage on shares of Tonix Pharmaceuticals in a research note on Wednesday, February 28th. They issued a “buy” rating and a $3.00 price objective for the company. StockNews.com began coverage on shares of Tonix Pharmaceuticals in a research report on Wednesday. They issued a “sell” rating for the company.

View Our Latest Analysis on TNXP

Tonix Pharmaceuticals Company Profile

(Get Free Report)

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.

Read More

Earnings History for Tonix Pharmaceuticals (NASDAQ:TNXP)

Receive News & Ratings for Tonix Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tonix Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.